natgillin/translations-raw huggingface dataset:
Caution: Artificial sweeteners and foods with artificial sweeteners (such as diet drinks) are of no help in treating hypoglycaemia.
Pozor: Umetna sladila in hrana z umetnimi sladili (kot so dietne pijače) pri zdravljenju hipoglikemijene pomagajo.
Caution: Artificial sweeteners and foods with artificial sweeteners (such as diet drinks) are of no help in treating hypoglycaemia.
Pozor: Umetna sladila in hrana z umetnimi sladili (kot so dietne pijače) pri zdravljenjuhipoglikemije ne pomagajo.
CAUTION: CELLCEPT I.V. SOLUTION MUST NOT BE ADMINISTERED BY RAPID OR BOLUS INTRAVENOUS INJECTION.
OPOZORILO: INTRAVENSKE RAZTOPINE ZDRAVILA CELLCEPT NE SMEMO DAJATI KOT HITRO INTRAVENSKO INJEKCIJO ALI V OBLIKI BOLUSA.
CAUTION: dilution required For single use only
Samo za enkratno uporabo.
CAUTION: dilution required For single use only.
Samo za enkratno uporabo.
Caution: dispenser graduated in millilitre (ml)
Pozor: peroralni odmernik ima merilno skalo v mililitrih (ml)
Caution: Do not push the dosage knob while inserting injection needle.
Pozor: Med vstavljanjem injekcijske igle ne pritiskajte gumba za namestitev odmerka.
CAUTION: Expel excess volume before injecting
OPOZORILO: Pred injiciranjem odstranite odvečni volumen.
CAUTION: Expel excess volume before injecting.
OPOZORILO: Pred injiciranjem odstranite odvečni volumen.
Caution: If you do not prime to a stream before each injection, you may get too much or too little insulin.
Opozorilo: Če injekcijskega peresnika ne pripravite do curka pred vsakim injiciranjem, lahko prejmete preveč  ali premalo insulina.
Caution: Keep the ampoules out of the reach of children.
Pozor: Ampule shranjujte nedosegljivo otrokom.
CAUTION: Since pre-filled syringe contains more medicinal product volume
OPOZORILO: Ker napolnjena injekcijska brizga vsebuje večji volumen zdravila
CAUTION: Since the pre-filled syringe contains more medicinal product volume
OPOZORILO: Ker napolnjena injekcijska brizga vsebuje večji volumen zdravila
Cautionary notes
Previdnostna opozorila
Cautious dose increase.
Previdno povečanje odmerka.
Cav = the average concentration when measured at steady state
Cav = povprečna koncentracija, merjena v stanju dinamičnega ravnovesja
Cav quartile analyses of pivotal patient studies with posaconazole tablet and oral suspension
Analiza kvartilov Cav ključnih študij pri bolnikih z uporabo tablet in peroralne suspenzije posakonazola
Caxton Road, Bedford, Bedfordshire, MK41 0XZ United Kingdom
Caxton Road, Bedford, Bedfordshire, MK41 0XZ Velika Britanija
Cayston contains the active substance aztreonam.
Zdravilo Cayston vsebuje zdravilno učinkovino aztreonam.
CAYSTON INNER CARTON
CAYSTON NOTRANJA ŠKATLA
Cayston is contained in a 2 ml amber glass vial with a grey rubber stopper and aluminium tear-off overseal with or without a blue cap.
Zdravilo Cayston je shranjeno v 2-ml rjavi stekleni viali s sivim gumijastim zamaškom in aluminijasto dvižno vrhnjo zaporko z modro zaporko ali brez nje.
Cayston may be taken in repeated cycles of 28 days on therapy followed by 28 days off Cayston therapy.
Zdravilo Cayston se lahko uporablja v ponavljajočih 28-dnevnih ciklih zdravljenja, ki jim sledi 28- dnevno obdobje brez jemanja zdravila Cayston.
CAYSTON OUTER CARTON
CAYSTON ZUNANJA ŠKATLA
Cayston should not be mixed with any other medicinal products in the Altera Nebuliser Handset.
Zdravila Cayston ne mešajte z drugimi zdravili v kompletu z nebulatorjem Altera.
Cayston should not be used with any other type of handset or aerosol head.
Zdravila Cayston se ne sme uporabljati z nobeno drugo vrsto kompleta ali glavo za izdelavo aerosola.
Cayston VIAL LABEL
Cayston NALEPKA NA VIALI
Cayston was compared to TNS over three 28-day courses of treatment in a randomised, active- controlled, multicenter study (GS-US-205-0110).
Zdravilo Cayston so primerjali z RTN v treh 28-dnevnih ciklih zdravljenja v randomizirani, aktivno kontrolirani multricentrični študiji (GS-US-205-0110).
Cayston was evaluated over a period of 28-days of treatment (one course) in two randomised, double- blind, placebo-controlled, multicentre studies (CP-AI-005 and CP-AI-007).
Zdravilo Cayston so ocenili v 28 dneh zdravljenja (en cikel zdravljenja) v dveh randomiziranih, dvojno-slepih, s placebom kontroliranih, multicentričnih študijah (CP-AI-005 in CP-AI-007).
Cbaseline (U/ml)
Cizhodišče (e/ml)
CBRe % of patients
CBRe % bolnikov z CB;
CC was defined as no vomiting and/or retching, no more than mild nausea and no rescue medicine from the first administration until 24 hours after the start of the last day’s administration of multi-day chemotherapy.
CC je bila opredeljena takole: nobenega bruhanja in/ali spahovanje, kvečjemu blaga navzea in nobenega rešilnega zdravila od prve uporabe do 24 ur po začetku dajanja večdnevne kemoterapije zadnjega dne.
cCCyRa 82.6%
cCCyRa
cCCyRa 83.0%
cCCyRa
CCID50 : Cell Culture Infective Dose 50%
CCID50: 50% infektivni odmerek za celično kulturo
CCID50 per dose
aluminijast
CCID50 per dose
CCID50 na odmerek
CCID50 per dose
na odmerek
CCID50 per dose
zaščitena z
CCID50 – the quantity of virus, which infects 50 % of the cell cultures inoculated.
CCID50 = količina virusa, ki inficira 50 % inokuliranih celičnih kultur
CCID50)
CCID50
CCR5 ANTAGONIST
ANTAGONISTI CCR5
CCR5 antagonist
CCR5 antagonisti
CCR5 Antagonists
antagonisti receptorjev CCR5
CCR5 inhibitors
Inhibitorji CCR5
CCR5 inhibitors
Zaviralci CCR5
CCR5 receptor antagonist
Antagonist receptorjev CCR5
CCR5-receptor antagonists
Antagonisti CCR5 receptorjev
CCyR (95% CI)
Popoln
CCyR, % (95% CI)
CCyR, % (95 % IZ)
CD Study I: Infliximab Naive Patients
Študija pri Crohnovi bolezni I: Bolniki, ki še niso dobivali infliksimaba
CD19, which is found on the surface of all B-cells, including ALL cells;
CD19, ki se nahaja na površini vseh celic z izvorom v liniji B, vključno s celicami ALL;
CD3 is expressed on mature T-cells as a component of the T-cell receptor.
CD3 je izražen na zrelih T- celicah kot sestavni del receptorja T-celice.
CD3 on the surface of T-cells (cells of the immune system responsible for killing pathogens and cancer cells).
CD3, ki se nahaja na površini celic T (celic imunskega sistema, ki so odgovorne za uničevanje patogenov in rakavih celic).
CD4 cell count (cells/mm3 ), median [range]
Število CD4 celic (celic/mm3), mediana [interval]
CD4 cell count (cells/mm3 ), median [range] 481 [0 – 2361]
Število CD4 celic (celic/mm3), mediana [interval] 481 [0 – 2361]
CD4 cell count (cells/mm3 ), median [range] 481 [0 – 2361]
Število celic CD4 (celic/mm3 ), mediana [razpon] 481 [0 – 2361]
CD4 cell count (cells/mm3 ), median [range] 481 [0 – 2361]
Število celic CD4 ≤ 50 celic/mm3
CD4 cell count mean change from baseline (x 106/l)b
Srednja vrednost spremembe števila celic CD4 glede na začetno vrednost (x 106/l)b
CD4 count
Število celic CD4
CD4 count < 350 cells/μl, n (%)
Število celic CD4 < 350/µl, n (%)
CD4 lymphocytes decreased,
bolečine v hrbtu, zmanjšano število limfocitov CD4,
CD4 lymphocytes decreased,
motnje presnove maščob, zmanjšano število limfocitov CD4,
CD4 Mean Change from Baseline, cells/mm3
Povprečna sprememba števila celic CD4 od izhodišča, celice/mm3
CD4 Mean Change from Baseline, cells/mm3
Srednja sprememba vrednosti števila celic CD4 od izhodišča, celice/mm3
CD4 Mean Change from Baseline, cells/mm3
Srednja sprememba števila celic CD4 od izhodišča, celice/mm3
CD4 Mean Change from Baseline, cells/mm3 by Baseline Characteristic
Srednja sprememba števila celic CD4 od izhodišča, celice/mm3 glede na izhodiščne lastnosti
CD4 median increase from baseline (x 106 cells/L)
Mediana zvišanja CD4 od začetka (x 106 celic/l)
CD4 percent, median [range]
Odstotek CD4 celic, mediana [interval]
CD4 percent, median [range] 23.3 % [0 – 44]
Odstotek CD4 celic, mediana [interval] 23,3 % [0 – 44]
CD4 percent, median [range] 23.3 % [0 – 44]
Odstotek CD4, mediana [razpon] 23,3 % [0 – 44]
CD4 T-cells are white blood cells that are important in helping to fight infections, but which are killed by HIV.
T-celice CD4 so bele krvne celice, ki imajo pomembno vlogo pri premagovanju okužb, vendar pa jih virus HIV uničuje.
CD4+ cell count Change from baseline (cells/mm3)#
število celic CD4+ Sprememba od izhodiščne vrednosti (celic/mm3) #
CD4+ cell count mean change from baseline (x 106/l)b
Število celic CD4+ - povprečna sprememba glede
CD4+ cell count mean change from baselineb
povprečna sprememba števila celic CD4+ od izhodiščab
CD4+ cell count mean change from baselineb
povprečna vrednost spremembe števila CD4+ celic glede na vrednost ob začetku zdravljenjab
CD4+ cell count mean change from baselineb
Št celic CD4+ povprečna sprememba glede na začetne vrednostib
CD4+ cell count mean change from baselineb
Število celic CD4+ sprememba glede na začetne vrednostib
CD4+ percent change from baseline
Število celic CD4+ sprememba odstotka glede na začetne vrednostib
CD4+ percent change from baselineb
Število celic CD4+ sprememba odstotka glede na začetne vrednostib
CD4+ T-cell count (cells/mm3)
Srednje povečanje števila T- celic CD4+ od začetka
CD4-count <50
Število CD4 celic <50
CD4-count ≤ 50 cells/mm3
> 50 in ≤ 200 celic/mm3
CD4-count ≤ 50 cells/mm3
Število celic CD4 ≤ 50 celic/mm3
CD4-count ≤ 50 cells/mm3 170 (122,
Število celic CD4 ≤ 50 celic/mm3 170 (122,
CDAI <150 at both Week 30 and 54 and not receiving corticosteroids in the 3 months prior to Week 54 among patients who were receiving corticosteroids at baseline.
CDAI< 150 tako v 30. tednu kot v 54. tednu, brez prejemanja kortikosteroidov v 3 mesecih pred 54. tednom pri bolnikih, ki so prejemali kortikosteroide na začetku študije
CDC Category C (%)
kategorija C (%) po CDC klasifikaciji
CDC class C
CDC razred C
CDC HIV category B or C
156 (121,
CDC HIV category B or C
CDC HIV kategorija B ali C
CDC HIV category B or C 59 %
CDC HIV kategorija B ali C 59
CDLQI of 0 or 1 indicates no effect on child’s quality of life.
CDLQI 0 ali 1 kažeta, da ni vpliva na otrokovo kakovost življenja.
CDLQI of 0 or 1b
CDLQI 0 ali 1bc
CDStudy I: Infliximab Naive Patients
Študija Crohnove bolezni I: bolniki, ki še niso prejemali infliksimaba
CDStudy I: Infliximab Naive Patients
Študija pri Crohnovi bolezni I: Bolniki, ki še niso dobivali infliksimaba
CE 0.45 mg/bazedoxifene 20 mg demonstrated similar changes in mammographic breast density compared to placebo over 1 year of treatment.
Po 1 letu zdravljenja so bile spremembe v gostoti dojk, ugotovljeni z mamografijo, podobne pri kombinaciji 0,45 mg CE/20 mg bazedoksifena in placebu.
CE marked pumps equivalent to the Synchromed and CADD-Micro pump should be used to deliver Prialt.
Za aplikacijo zdravila Prialt morajo biti uporabljene s CE označene črpalke, ekvivalentne Synchromed in CADD-Micro črpalki.
CE/bazedoxifene can be administered with or without food.
Kombinacijo CE/bazedoksifena se lahko daje s hrano ali brez nje.
CE/bazedoxifene has not been studied in patients with impaired liver function (see sections 4.2 and 5.2) or history of cholestatic jaundice.
Kombinacije CE/bazedoksifena pri bolnicah z okvarjenim delovanjem jeter (glejte poglavji 4.2 in 5.2) ali holestatskim ikterusom v anamnezi niso raziskovali.
CE/bazedoxifene has not been studied in women aged 75 years or older.
Kombinacije CE/bazedoksifena pri ženskah, starih 75 let ali več, niso raziskovali.
CE/bazedoxifene has not been studied in women with baseline triglyceride levels >300 mg/dL (>3.4 mmol/L).
Kombinacije CE/bazedoksifena pri ženskah z izhodiščnimi vrednostmi trigliceridov > 300 mg/dl (> 3,4 mmol/l) niso raziskovali.
CEA Responsea
Odziv CEAa
Cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections
cefaklor, benzilpenicillin (penicillin G), ciprofloksacin za okužbe,
Cefovecin differs from other similar cephalosporin antibiotics as it stays in the dog’s or cat’s body for a very long time after it has been injected.
Cefovecin se od drugih podobnih cefalosporinskih antibiotikov razlikuje po tem, da ostane v telesu psa ali mačke še zelo dolgo po injiciranju.
Cefovecin exhibits in vitro activity against Staphylococcus pseudintermedius and Pasteurella multocida which are associated with canine and feline skin infections.
Cefovecin kaže in-vitro učinkovitost proti Staphylococcus pseudintermedius in Pasteurella multocida, ki sta povezani z infekcijo kože pri psih in mačkah.
Cefovecin exhibits in-vitro activity against Staphylococcus pseudintermedius and Pasteurella multocida which are associated with canine and feline skin infections.
Cefovecin kaže in-vitro učinkovitost proti Staphylococcus pseudintermedius in Pasteurella multocida, ki sta povezani z infekcijo kože pri psih in mačkah.
Ceftaroline fosamil and ceftaroline were clastogenic in an in vitro chromosomal aberration assay, however there was no evidence of mutagenic activity in an Ames, mouse lymphoma and unscheduled DNA synthesis assay.
Fosamilceftarolin in ceftarolin sta bila klastogena v preizkusu kromosomskih aberacij in vitro, a Amesov test, preizkus z mišjim limfomom in preizkus nenačrtne sinteze DNA niso pokazali znakov mutagenega delovanja.
Ceftazidime belongs to the group of antibiotics called “cephalosporins”.
Ceftazidim spada v skupino antibiotikov, imenovanih "cefalosporini".
Ceftazidime does not interfere with enzyme-based tests for glycosuria.
Ceftazidim ne vpliva na encimske teste glikozurije.
Ceftazidime inhibits bacterial peptidoglycan cell wall synthesis following binding to penicillin binding proteins (PBPs), which leads to bacterial cell lysis and death.
Ceftazidim z vezavo na penicilin vezavne proteine (PBP – penicillin binding proteins) zavre sintezo peptidoglikana bakterijske celične stene in tako povzroči lizo in odmrtje bakterijske celice.
Ceftazidime is an antibiotic called a cephalosporin, which belongs to the wider group ‘beta-lactams’.
Ceftazidim je antibiotik, imenovan cefalosporin, ki spada v širšo skupino betalaktamov.
Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80-90% of the dose is recovered in the urine within 24 h.
Ceftazidim se nespremenjen izloča v urinu z glomerulno filtracijo; približno 80 do 90 % odmerka se v 24 urah pojavi v urinu.
Ceftazidime/avibactam should only be used during pregnancy if the potential benefit outweighs the possible risk.
Kombinacijo ceftazidima in avibaktama se sme med nosečnostjo uporabiti le, če morebitne koristi upravičujejo možno tveganje.
Ceftiofur (as crystalline free acid) 100 mg,
Ceftiofur (kot kristalinična prosta kislina) 100 mg,
Ceftiofur (as crystalline free acid) 100 mg/ml, Oily vehicle (vegetable origin).
Ceftiofur (kot kristalinična prosta kislina) 100 mg/ml Oljni vehikel (rastlinski izvor).
Ceftiofur (as crystalline free acid) 100 mg/ml.
Ceftiofur (kot kristalinična prosta kislina) 100 mg/ml
Ceftiofur (as crystalline free acid) 200 mg,
Ceftiofur (kot kristalinična prosta kislina) 200 mg,
Ceftiofur (as crystalline free acid) 200 mg/ml Oily vehicle (vegetable origin).
Ceftiofur (kot kristalinična prosta kislina) 200 mg/ml Oljni vehikel (rastlinski izvor)
Ceftiofur (as crystalline free acid) 200 mg/ml.
Ceftiofur (kot kristalinična prosta kislina) 200 mg/ml
Ceftiofur inhibits the bacterial cell wall synthesis, thereby exerting bactericidal properties.
Ceftiofur zavira sintezo bakterijske stene in tako kaže baktericidno aktivnost.
Ceftiofur is a third generation cephalosporin antibiotic, which is active against many Gram-positive and Gram-negative pathogens.
Ceftiofur je cefalosporinski antibiotik tretje generacije, ki je aktiven proti številnim gramnegativnim in grampozitivnim povzročiteljem.
Ceftiofur is particularly active against the following target pathogens causing respiratory and other diseases in pigs: Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis.
Ceftiofur je aktiven predvsem proti naslednjim povzročiteljem respiratornih in drugih obolenj pri prašičih: Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis in Streptococcus suis.
Ceftolozane exerts bactericidal activity through binding to important penicillin-binding proteins (PBPs), resulting in inhibition of bacterial cell-wall synthesis and subsequent cell death.
Ceftolozan deluje baktericidno z vezavo na pomembne beljakovine, ki vežejo penicilin (PBP – penicillin-binding proteins), ter s tem zavre sintezo bakterijske celične stene in posledično povzroči celično smrt.
ceftolozane, an antibiotic that belongs to the group of “cephalosporins” and which can kill certain bacteria that can cause infection; tazobactam, which blocks the action of certain enzymes called beta lactamases.
ceftolozan, antibiotik iz skupine cefalosporinov, ki uničuje določene bakterije, ki lahko povzročajo okužbe, tazobaktam, ki zavre delovanje določenih encimov, imenovanih betalaktamaze.
Ceftolozane/tazobactam contains 10.0 mmol (230 mg) of sodium per vial.
Kombinacija ceftolozana/tazobaktama vsebuje 10,0 mmol (230 mg) natrija na vialo.
Ceftolozane/tazobactam is also contraindicated in patients with severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or carbapenems) (see section 4.3).
Kombinacija ceftolozana/tazobaktama je kontraindicirana tudi pri bolnikih s hudo preobčutljivostjo (npr. anafilaktično reakcijo, hudo kožno reakcijo) na katero koli vrsto betalaktamskih antibiotikov (npr. na peniciline ali karbapeneme) (glejte poglavje 4.3).
Ceftriaxone
ceftriakson
celecoxib (used to treat some forms of inflamamtion),
celekoksib (uporablja se za zdravljenje nekaterih vrst vnetja),
Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide to a clinically relevant extent.
Celekoksib ne vpliva klinično pomembno na farmakokinetiko tolbutamida (substrat CYP2C9) ali glibenklamida.
Celecoxib inhibits tumour formation in preclinical models of colon cancer, which overexpress COX-2, whether induced by chemical (rat AOM model) or genetic (MIN mouse model) mutation.
V predkliničnih modelih karcinoma na kolonu s prekomerno izraženo COX-2 celekoksib zavira nastanek tumorjev, izzvanih s kemično (model podgan AOM) ali genetsko (model miši MIN) mutacijo.
Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differing from arylamine sulfonamides (e.g. sulfamethoxizole and other sulfonamide antibiotics).
Celekoksib je diaril-substituiran pirazol, kemično podoben drugim nearilaminskim sulfonamidom (npr. tiazidom, furosemidu), a drugačen od arilaminskih sulfonamidov (npr. sulfametoksazola in drugih sulfonamidnih antibiotikov).
Celecoxib metabolism is primarily mediated via cytochrome P450 2C9.
Presnova celekoksiba poteka predvsem prek citokroma P450 CYP2C9.
Celgene Europe Ltd., 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, United Kingdom.
Celgene Europe Ltd., 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Združeno kraljestvo
Cell suspension: Store and transport frozen in liquid nitrogen (–196 °C).
Suspenzija celic: Shranjujte in prevažajte zmrznjeno v tekočem dušiku.
cell transplantation
odmerek:
Cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain: 2,500 – 8,000 PFU*
Celično vezan živ rekombinantni puranji herpes virus (rHTV/ND), ki izraža fuzijski protein virusa atipične kokošje kuge (Newcastle bolezni) D-26 lentogen sev: 2.500 – 8.000 PFU
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus: 103.1 – 104.1 PFU1.
Na celico vezan živ rekombinantni puranji herpes virus (sev HVT/ILT- 138) z izraženima glikoproteinoma gD in gI virusa kužnega laringotraheitisa: 103.1 – 104.1 PFU1
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus: 103.1 – 104.1 PFU1.
Na celico vezan živ rekombinantni puranji herpes virus z izraženima glikoproteinoma gD in gI virusa kužnega laringotraheitisa, sev HVT/ILT- 138: 103.1 – 104.1 PFU1
CellCelpt contains sorbitol (a type of sugar).
Zdravilo CellCept vsebuje sorbitol (vrsta sladkorja).
CellCept 1 g/5 ml powder for oral suspension sorbitol
CellCept 1 g/5 ml prašek za peroralno suspenzijo: sorbitol
CellCept 1 g/5 ml powder for oral suspension.
CellCept 1 g/5 ml prašek za peroralno suspenzijo
CellCept 1 g/5 ml powder for oral suspension:
CellCept 1 g/5 ml prašek za peroralno suspenzijo:
CellCept 250 mg capsules.
CellCept 250 mg kapsule
CellCept 250 mg capsules: 1 carton contains 100 capsules (in blister packs of 10)
CellCept 250 mg kapsule: 1 škatla s 100 kapsulami (v pretisnih omotih po 10 kapsul)
CellCept 500 mg film-coated tablets Mycophenolate mofetil
CellCept 500 mg filmsko obložene tablete mofetilmikofenolat
CellCept 500 mg film-coated tablets.
CellCept 500 mg filmsko obložene tablete
CellCept 500 mg powder for concentrate for solution for infusion
CellCept 500 mg prašek za koncentrat za raztopino za infundiranje
CellCept 500 mg powder for concentrate for solution for infusion does not contain an antibacterial preservative; therefore, reconstitution and dilution of the product must be performed under aseptic conditions.
Zdravilo CellCept 500 mg prašek za koncentrat za raztopino za infundiranje ne vsebuje konzervansov, zato mora priprava in razredčitev zdravila potekati aseptično.
CellCept 500 mg powder for concentrate for solution for infusion polysorbate 80 citric acid hydrochloric acid sodium chloride
CellCept 500 mg prašek za koncentrat za raztopino za infundiranje: polisorbat 80 citronska kislina klorovodikova kislina natrijev klorid
CellCept 500 mg powder for concentrate for solution for infusion.
CellCept 500 mg prašek za koncentrat za raztopino za infundiranje
CellCept capsules are oblong shaped with one end blue and the other end brown.
CellCept kapsule so ovalne oblike, en del kapsule je modre, drugi del pa rjave barve.
CellCept capsules should be handled with care
CellCept kapsule je treba uporabljati previdno Kapsul ne odpirajte in ne drobite
CellCept contains aspartame.
Zdravilo CellCept vsebuje aspartam.
CellCept film-coated tablets should be handled with care Do not crush the tablets
CellCept filmsko obložene tablete je treba uporabljati previdno Tablet ne drobite
CellCept is contraindicated in women of childbearing potential who are not using highly effective contraception.
Zdravilo CellCept je kontraindicirano pri bolnicah v rodni dobi, ki ne uporabljajo zelo učinkovitih kontracepcijskih metod.
CellCept is not likely to affect you being able to drive or use any tools or machines.
Ni verjetno, da bi zdravilo CellCept vplivalo na vašo sposobnost vožnje in upravljanje z orodji ali stroji.
Cellcept is provided in a 20 mL type I clear glass vial with a grey butyl rubber stopper and aluminium seal with a plastic flip-off cap.
Zdravilo CellCept je na voljo v 20 ml viali iz bistrega stekla tipa I s sivim zamaškom iz butilne gume, hermetično zaprte z aluminijastim pokrovom s plastično zaporko, ki se odstrani.
CellCept reduces your body’s defences.
Zdravilo CellCept zmanjša obrambno sposobnost vašega organizma.
CellCept should be administered with caution in patients with active serious digestive system disease.
Bolnikom s hujšimi boleznimi prebavil v aktivnih fazah zato dajemo zdravilo CellCept zelo previdno in pod skrbnim zdravniškim nadzorom.
CellCept should be administered with caution in patients with active serious digestive system disease.
Bolnikom s hujšimi boleznimi prebavil v aktivnih fazah zato dajemo zdravilo CellCept zelo previdno.
CellCept should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1. Hypersensitivity reactions to CellCept have been observed (see section 4.8).
Zdravila Cellcept ne smemo uporabljati pri bolnikih s preobčutljivostjo za mofetilmikofenolat, mikofenolno kislino ali katero koli pomožno snov, navedeno v poglavju 6.1. Opazili so preobčutljivostne reakcije na zdravilo CellCept (glejte poglavje 4.8).
CellCept should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6).
Zdravila CellCept ne smemo uporabljati pri bolnicah v rodni dobi, ki ne uporabljajo zelo učinkovitih kontracepcijskih metod (glejte poglavje 4.6).